Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETC-159 + Pembrolizumab in Advanced MSS/pMMR Ovarian Cancer
NCT06513624Phase 1Recruiting
- Sponsor
- National University Hospital
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ETC-159 in ovarian cancer, sponsored by National University Hospital. Primary endpoints: Disease Control Rate at 1 year, Objective Response Rate at 1 year and 1 more. Started Dec 2024; status: recruiting.
02
Drugs
ETC-159
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06513624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06513624.